Empower early detection of metabolic-associated steatotic
liver disease (MASLD) with ACUSON Sequoia, offering
comprehensive liver assessments to enhance patient care and
reduce invasive procedures.
Early detection plays a key role in managing and potentially reversing
MASLD,1 which often progresses without noticeable symptoms. This can
lead to severe complications such as liver transplants and hepatocellular
carcinoma.2 Increasing access to noninvasive, cost-effective screenings
is essential in addressing this growing health concern.
Touch screen, 33.782 cm (13.3 inch) diagonal, LCD widescreen
Transducer ports
Supports four active transducer ports
Meet the Solutions
Ultrasound Derived Fat
Fraction (UDFF)
UDFF can quantify the amount of fat within a patient’s liver quickly and painlessly in just seconds during a routine abdominal ultrasound.4 UDFF on ACUSON Sequoia shows a good agreement with MRI Proton Density Fat Fraction (MRI-PDFF) to aid clinicians in determining hepatic steatosis. MRI-PDFF and UDFF methods classify hepatic steatosis as an index value greater than 5%.5
Auto Point Shear Wave
Elastography (Auto pSWE)
Auto Point Shear Wave Elastography (Auto pSWE) technology offers rapid, reproducible liver stiffness measurements. Historically, point shear wave elastography (pSWE) required individual acquisitions. With Auto pSWE, the process is automated, ensuring up to 15 valid assessments in under one minute and reducing exam time by up to 50%.6
Deep Abdominal
Transducer (DAX)
The ACUSON Sequoia’s Deep Abdominal Transducer (DAX) provides increased diagnostic confidence in patient populations limited by conventional ultrasound technology. DAX has the capability to image at diagnostic depths of up to 55 cm, while also reducing the need for excessive transducer pressure.
Precision Meets Innovation
Experience comprehensive liver care with ACUSON Sequoia’s automated imaging technology.